Artificial Tertiary Lymphoid Structures: Exploring Mesenchymal Stromal Cells As a Platform for Immune Niche Formation

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2025 Jan 8

PMID 39769051

Authors

Ekaterina Zubkova

Alexander Kalinin

Irina Beloglazova

Ella Kurilina

Mikhail Menshikov

Yelena Parfyonova

Zoya Tsokolaeva

Affiliations

Soon will be listed here.

Abstract

Constructing artificial tertiary lymphoid structures (TLSs) opens new avenues for advancing cancer immunotherapy and personalized medicine by creating controllable immune niches. Mesenchymal stromal cells (MSCs) offer an ideal stromal source for such constructs, given their potent immunomodulatory abilities and accessibility. In this study, we explored the potential of adipose-derived MSCs to adopt TLS-supportive phenotypes and facilitate lymphocyte organization. Single-cell RNA sequencing revealed a distinct subpopulation of MSCs expressing key fibroblastic reticular cell (FRC)-associated markers, including IL-7, PDPN, and IL-15, though lacking follicular dendritic cell (FDC) markers. TNF-α stimulation, but not LTα2β1, further enhanced FRC marker expression (IL-7, PDPN, and ICAM1). Notably, in 3D spheroid co-culture with lymphocytes, MSCs upregulated additional FRC markers, specifically CCL21. Upon implantation into adipose tissue, MSC-lymphocyte organoids maintained structural integrity and showed extensive T-cell infiltration and partial vascularization after 15 days in vivo, although organized B-cell follicles and FDC markers were still lacking. These findings highlight MSCs' intrinsic ability to adopt an FRC-like phenotype that supports T-cell and HEV organization, suggesting that further optimization, including genetic modification, may be needed to achieve an FDC phenotype and replicate the full architectural and functional complexity of TLSs.

References

Sautes-Fridman C, Petitprez F, Calderaro J, Fridman W . Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019; 19(6):307-325. DOI: 10.1038/s41568-019-0144-6. View

Goc J, Germain C, Vo-Bourgais T, Lupo A, Klein C, Knockaert S . Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 2013; 74(3):705-15. DOI: 10.1158/0008-5472.CAN-13-1342. View

Burkholder B, Huang R, Burgess R, Luo S, Jones V, Zhang W . Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta. 2014; 1845(2):182-201. DOI: 10.1016/j.bbcan.2014.01.004. View

Krautler N, Kana V, Kranich J, Tian Y, Perera D, Lemm D . Follicular dendritic cells emerge from ubiquitous perivascular precursors. Cell. 2012; 150(1):194-206. PMC: 3704230. DOI: 10.1016/j.cell.2012.05.032. View

Link A, Vogt T, Favre S, Britschgi M, Acha-Orbea H, Hinz B . Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat Immunol. 2007; 8(11):1255-65. DOI: 10.1038/ni1513. View

Zhu G, Nemoto S, Mailloux A, Perez-Villarroel P, Nakagawa R, Falahat R . Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line. Front Immunol. 2018; 9:1609. PMC: 6054958. DOI: 10.3389/fimmu.2018.01609. View

Carretta M, de Boer B, Jaques J, Antonelli A, Horton S, Yuan H . Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models. Exp Hematol. 2017; 51:36-46. DOI: 10.1016/j.exphem.2017.04.008. View

Dorraji S, Hovd A, Kanapathippillai P, Bakland G, Eilertsen G, Figenschau S . Mesenchymal stem cells and T cells in the formation of Tertiary Lymphoid Structures in Lupus Nephritis. Sci Rep. 2018; 8(1):7861. PMC: 5959845. DOI: 10.1038/s41598-018-26265-z. View

Anselmi G, Vaivode K, Dutertre C, Bourdely P, Missolo-Koussou Y, Newell E . Engineered niches support the development of human dendritic cells in humanized mice. Nat Commun. 2020; 11(1):2054. PMC: 7189247. DOI: 10.1038/s41467-020-15937-y. View

10.

Pievani A, Savoldelli R, Poelchen J, Mattioli E, Anselmi G, Girardot A . Harnessing Mesenchymal Stromal Cells for the Engineering of Human Hematopoietic Niches. Front Immunol. 2021; 12:631279. PMC: 8006008. DOI: 10.3389/fimmu.2021.631279. View

11.

Sato Y, Silina K, van den Broek M, Hirahara K, Yanagita M . The roles of tertiary lymphoid structures in chronic diseases. Nat Rev Nephrol. 2023; 19(8):525-537. PMC: 10092939. DOI: 10.1038/s41581-023-00706-z. View

12.

Arai H, Sato Y, Yanagita M . Fibroblast heterogeneity and tertiary lymphoid tissues in the kidney. Immunol Rev. 2021; 302(1):196-210. PMC: 8360208. DOI: 10.1111/imr.12969. View

13.

Frasca D, Blomberg B . Adipose Tissue: A Tertiary Lymphoid Organ: Does It Change with Age?. Gerontology. 2019; 66(2):114-121. PMC: 7018534. DOI: 10.1159/000502036. View

14.

Klaus G, Humphrey J, Kunkl A, Dongworth D . The follicular dendritic cell: its role in antigen presentation in the generation of immunological memory. Immunol Rev. 1980; 53:3-28. DOI: 10.1111/j.1600-065x.1980.tb01038.x. View

15.

Cheng H, Onder L, Novkovic M, Soneson C, Lutge M, Pikor N . Origin and differentiation trajectories of fibroblastic reticular cells in the splenic white pulp. Nat Commun. 2019; 10(1):1739. PMC: 6465367. DOI: 10.1038/s41467-019-09728-3. View

16.

Sato Y, Mii A, Hamazaki Y, Fujita H, Nakata H, Masuda K . Heterogeneous fibroblasts underlie age-dependent tertiary lymphoid tissues in the kidney. JCI Insight. 2016; 1(11):e87680. PMC: 5033938. DOI: 10.1172/jci.insight.87680. View

17.

Bui T, Wiesolek H, Sumagin R . ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J Leukoc Biol. 2020; 108(3):787-799. PMC: 7977775. DOI: 10.1002/JLB.2MR0220-549R. View

18.

Gago da Graca C, van Baarsen L, Mebius R . Tertiary Lymphoid Structures: Diversity in Their Development, Composition, and Role. J Immunol. 2021; 206(2):273-281. DOI: 10.4049/jimmunol.2000873. View

19.

Aggarwal B, Vijayalekshmi R, Sung B . Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009; 15(2):425-30. DOI: 10.1158/1078-0432.CCR-08-0149. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View